glp jdc burst 1 1: The next evolution of the legendary JDC1 GLP JDC Burst 1 –

Altimmune just made a big move in the world of GLP-1 research, but this time, its not about obesity.The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD

He completed his BSc(hons), MSc and PhD at Leeds Beckett University, prior to becoming a Senior Lecturer in Sport and Exercise Physiology, then receiving his Professorship in 2017, at the age of 31.

Dining out on GLP-1s is possible

SReference: Hviid KVR et al

Specifically, GLP-1 RAs showed significantly reduced risks of progression to systolic heart failure (HR 0.60) and stroke (HR 0.75) compared to SGLT2 inhibitors

Mounting research suggests GLP-1 drugs, which are used to treat diabetes and obesity, may one day help people with alcohol use disorder